FDA Brief

Warning letters Food

FDA warning letter to

Meta Labs Pharmaceuticals, LLC

High riskIssued May 15Posted Jun 2Human Foods Program

FDA warns Meta Labs its supplements are unapproved drugs and have serious manufacturing violations.

What happened

FDA inspected Meta Labs' facility from December 8 through December 18, 2025, and reviewed product labels and the website www.metalabsinc.com in April 2026. FDA found disease-treatment claims that make several supplements unapproved new drugs and misbranded drugs, plus violations of Current Good Manufacturing Practice (CGMP) in finished product specifications, component specifications, master and batch manufacturing records, and laboratory controls. The firm had not responded to the Form FDA 483 (inspection observations) issued at the inspection.

What FDA found

  1. The products are unapproved new drugs because website and label claims say they cure, mitigate, treat, or prevent diseases such as diabetes, viral infections, asthma, and heart disease.

    section 201(g)(1)(B), 201(p) of the Act [21 U.S.C. 321(g)(1)(B), 321(p)]; sections 301(d), 505(a) [21 U.S.C. 331(d), 355(a)]
  2. The products are misbranded because they lack adequate directions for use for diseases that are not suitable for self-treatment without a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  3. The company did not establish finished product specifications for identity, purity, strength, composition, and contamination limits for Diabetic Advantage and Respiratory Response.

    21 CFR 111.70(e); 21 CFR 111.75(c)
  4. The company did not establish component identity specifications and purity, strength, composition, and contamination specifications for all dietary ingredients used.

    21 CFR 111.70(b); 21 CFR 111.75(a)
  5. Master manufacturing records and batch production records for Diabetic Advantage and Respiratory Response lacked required details such as ingredient identity and weight, theoretical yield, packaging description, process specifications, cleaning times, yield results, quality review documentation, and label quantities.

    21 CFR 111.205(b)(1), 111.210, 111.255(b), 111.260
  6. The company did not establish and follow quality-control laboratory processes for selecting reference materials, because it compared each finished product against the most recently manufactured batch.

    21 CFR 111.315(d)

What FDA wants

FDA asks the company to respond in writing within 15 working days describing specific corrective steps, with documentation and plans to prevent recurrence, or explain why it believes it is not in violation. If corrections cannot be completed in that time, the company must state the reason and when it will finish.

Who should pay attention

  • dietary supplement brands using contract manufacturers
  • retailers and distributors selling supplement products with disease claims
  • quality teams managing supplement CGMP records and supplier specifications

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk